Skip to main content

Table 2 Number and proportions of patients who achieved humoral response at week 5 by subgroup

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

 

PCV-13

TTV

Overall baricitinib group (N = 106)

70 (68)

44 (43)

Concomitant corticosteroids

 Yes (N = 31)

22 (71)

16 (52)

 No (N = 72)

48 (67)

28 (39)

Age group

 Patients < 65 years (N = 80)

59 (74)

37 (46)

 Patients ≥ 65 years (N = 23)

11 (48)

7 (32)

SDAI prior to vaccination

 ≤ 3.3 (N = 21)

13 (62)

11 (55)

 > 3.3 and ≤ 11 (N = 47)

34 (72)

20 (43)

 > 11 (N = 32)

21 (66)

13 (41)

Baricitinib dose

 2 mg (N = 16)

11 (69)

5 (33)

 4 mg (N = 87)

59 (68)

39 (45)

  1. Data are reported as n (%). PCV-13 satisfactory humoral response defined as a ≥ 2-fold increase from baseline in antibody concentrations in ≥ 6 of the 13 pneumococcal serotypes. TTV satisfactory humoral response defined as a ≥ 4-fold increase from baseline in anti-tetanus concentration in patients with baseline anti-tetanus IgG concentration ≥ 0.1 IU/mL
  2. PCV-13 13-serotype pneumococcal conjugate vaccine, SDAI Simplified Disease Activity Index, TTV tetanus toxoid vaccine
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us